The EPS projection of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) for quarter ended 2016-09-30 is $-0.19. Last week, the EPS forecast was $-0.19 against target of $-0.19, a month earlier. Two months ago, this estimate was $-0.19 versus forecast of $-0.19 three months earlier, implying a deviation of 0%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 2, 3, and 2, correspondingly.
EPS estimate downgrade for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) in the preceding 30, 120, 60 and 90 days were 1, 0, 0, and 0, correspondingly.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) EPS target for the quarter closed 1 was $-0.19, based on 4 recommendations. As reported on 2016-05-10 the EPS was $-0.28. The change was $0.01, implying a percentage deviation of 3.45%. The projections showed a standard deviation of 0.09.
Quarterly Sales Estimates
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly sales prediction for the fiscal 2016 stands at $50.827 and the median estimate is at $50.827. Almost 2 analysts issued sales target.
Highest sales target is $57.412 while the lowest target is $44.242 showing standard deviation of 9.312%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of 0.001%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the deviation in forecast was -1.595%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...